

# Developing Medical Extended Reality Devices: Sponsor Perspective

---


Patient Engagement Advisory Committee Meeting  
July 12-13, 2022

Jennifer N Avari Silva, MD, CCEP-PC, FHRS, FAHA, FACC  
Co-Founder & Co-Inventor, Sentiar  
Co-Founder & Co-Inventor, Excera


Director, Pediatric Electrophysiology  
Professor, Pediatrics and Biomedical Engineering  
Faculty Fellow in Entrepreneurship  
Washington University in St. Louis



# Medical Extended Reality Device Development



- Always start with the unmet need (unarticulated need)
- Is MXR the correct type of *enabling technology* for this project?
- If so, what type of MXR?



*“I suppose it is tempting, if the only tool you have is a hammer, to treat everything as if it were a nail.”*

*--Abraham H. Maslow (1962)  
Toward a Psychology of Being*

Identify the Problem

# The Problem in Interventional EP




Visualization · Control

# CommandEP™ System

## SentiAR Engine and Current V2 Application

Electroanatomic Mapping System




SentiAR Software Enabled  
Magic Leap 2 Display



CONNECTS multiple  
sources of data and  
allows for collaboration  
using secure protocols

Provides a real time 3D  
Hologram

VISUALIZATION



Gives physicians  
CONTROL of the model  
manipulation

*Provides a platform to build a widgetized dashboard for the entire procedure*

# Video of CommandEP™ System



## Lessons Learned during Development

The Digital  
Space

User  
interface

User  
experience

Technical  
Specifications



# Lessons Learned From Clinical Study

## System Usability

- Often clinical or other HCP facing outcome measure

## Outcomes

- Identifying patient-facing outcomes is key
- Think creatively about outcomes that meaningfully impact patients
- Find outcomes that are discrete and measurable
- Talk to patients and see if they can help sponsors and investigators understand what those may be

# Considerations for Patient Consent in Clinical Studies Emerging Technologies

## General Considerations:

Allow plenty of time for discussion

Answer questions clearly and  
honestly

Show patients what the technology  
looks like

## Considerations for vulnerable populations:

“Seeing is believing”


Complete device demonstrations  
**after** consent/assent is complete  
(avoid the appearance of coercion)




# Acknowledgements



Jonathan Silva  
Michael Southworth  
Berk Tas



Office of Technology Management (OTM)



R44 HL140896-03  
CH-II-2017-575  
BC-2016-5  
R43 HL147745-01



F Creighton  
M Faddis  
S Jain

